- Trials with a EudraCT protocol (252)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
252 result(s) found for: Melanoma (Skin) AND Cancer.
Displaying page 7 of 13.
EudraCT Number: 2005-004710-33 | Sponsor Protocol Number: CAMEL 02 | Start Date*: 2006-02-24 |
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust | ||
Full Title: A PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PTK787 IN PATIENTS WITH METASTATIC CUTANEOUS MELANOMA | ||
Medical condition: Metastatic cutaneous melanoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-003895-15 | Sponsor Protocol Number: 82720 | Start Date*: 2022-02-23 | ||||||||||||||||
Sponsor Name:Bispebjerg Hospital, Department of Dermatology and Venereology | ||||||||||||||||||
Full Title: Impact of human papillomavirus (HPV) vaccination on burden of disease in patients with actinic keratosis ― a double-blind randomized controlled trial | ||||||||||||||||||
Medical condition: Actinic Keratosis (AK) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003064-27 | Sponsor Protocol Number: PH-L19IL2TNF-01/18 | Start Date*: 2022-02-25 | |||||||||||
Sponsor Name:Philogen S.p.A. | |||||||||||||
Full Title: An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and ... | |||||||||||||
Medical condition: Malignant melanoma of the skin in patients with locally advanced and fully resectable melanoma with/without prior therapy and presence of injectable cutaneous and/or subcutaneous or nodal lesions | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001266-15 | Sponsor Protocol Number: BRF115532 | Start Date*: 2013-02-13 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: COMBI-AD: A phase III randomized double blind study of dabrafenib (GSK2118436) in COMBInation with trametinib (GSK1120212) versus two placebos in the ADjuvant treatment of high-risk BRAF V600 muta... | |||||||||||||
Medical condition: High-risk BRAF V600 mutation-positive melanoma after surgical resection. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) SE (Completed) CZ (Completed) DE (Completed) NO (Completed) GB (Completed) AT (Completed) GR (Completed) IT (Completed) NL (Completed) DK (Completed) ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002147-29 | Sponsor Protocol Number: BO43328 | Start Date*: 2021-11-30 | |||||||||||
Sponsor Name:Roche Farma S. A. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TREATMENT COMBINATIONS IN PATIENTS WITH MELANOMA | |||||||||||||
Medical condition: Melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) FR (Completed) IT (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002243-42 | Sponsor Protocol Number: GCT1021-01 | Start Date*: 2016-10-25 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Genmab A/S | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (enapotamab vedotin, HuMax®-AXL-ADC) in patients with solid tumors. | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Cancer of the ovary, cervix, endometrium, anaplastic thyroid, lung (non-small cell lung cancer [NSCLC]) or melanoma | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-001911-22 | Sponsor Protocol Number: N19TVN | Start Date*: 2020-06-04 | |||||||||||||||||||||
Sponsor Name:Antoni van Leeuwenhoek Ziekenhuis | |||||||||||||||||||||||
Full Title: Neo-adjuvant T-VEC + NivolumabAnti-PD-1 combination therapy for resectable early metastatic (stage IIIB/C/D-IV M1a) melanoma with injectable disease | |||||||||||||||||||||||
Medical condition: Patients with early metastatic (stage IIIB/C/D/IV M1a (AJCC 8)) melanoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004577-12 | Sponsor Protocol Number: BRF116613 | Start Date*: 2015-03-23 | |||||||||||
Sponsor Name:GlaxoSmithKline, S.A. | |||||||||||||
Full Title: Phase II biomarker study evaluating the upfront combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib versus the combination after eight weeks of monotherapy with dabrafenib or tra... | |||||||||||||
Medical condition: patients with metastatic and unresectable stage III or IV melanoma harbouring an activating BRAF mutation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002206-52 | Sponsor Protocol Number: CD-ON-MEDI4736-1108 | Start Date*: 2012-12-05 |
Sponsor Name:MedImmune | ||
Full Title: A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects with Advanced Solid Tumors | ||
Medical condition: Advanced Solid Tumors | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) GB (Completed) DK (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2017-003556-23 | Sponsor Protocol Number: PROMIT | Start Date*: 2019-10-15 | |||||||||||
Sponsor Name:University Hospital of the Friedrich-Alexander University Erlangen-Nürnberg | |||||||||||||
Full Title: A Phase 2, single arm study on dacarbazine (DTIC) followed by immunotherapy re-challenge in unresectable or metastatic melanoma with primary resistance to PD-1/PD-L1 or PD-1 + CTLA4 Blockade Pre... | |||||||||||||
Medical condition: Melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001469-34 | Sponsor Protocol Number: NEO-CESQ | Start Date*: 2020-10-20 | |||||||||||
Sponsor Name:FONDAZIONE MELANOMA ONLUS | |||||||||||||
Full Title: A phase II, single arm study investigating neoadjuvant plus adjuvant treatment with Cemiplimab in high risk, surgically resectable, stage III Cutaneaous Squamous Cell Carcinoma | |||||||||||||
Medical condition: high risk, surgically resectable, stage III Cutaneous Squamous Cell Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004380-40 | Sponsor Protocol Number: CA209-76U | Start Date*: 2020-11-27 | |||||||||||||||||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||||||||||||||||||||||
Full Title: A Phase 1/2 Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Ipilimumab Monotherapy and in Combination with Subcutaneous Nivolumab | |||||||||||||||||||||||||||||||||
Medical condition: The study population will include participants diagnosed with metastatic melanoma, advanced/metastatic urothelial carcinoma (mUC), advanced hepatocellular carcinoma (HCC) in Part 1, and metastatic... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-001959-37 | Sponsor Protocol Number: E7449-E044-101 | Start Date*: 2011-10-17 | |||||||||||||||||||||||||||||||
Sponsor Name:Eisai Limited | |||||||||||||||||||||||||||||||||
Full Title: An open label, multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects with Advanced Solid Tumours or with B-cell Malignancies and in Combinat... | |||||||||||||||||||||||||||||||||
Medical condition: Advanced solid tumors (including ovarian cancer, triple negative breast cancer, and advanced melanoma) and B-cell lymphomas | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-000899-19 | Sponsor Protocol Number: EVX-01-001 | Start Date*: 2022-09-16 |
Sponsor Name:Evaxion Biotech A/S | ||
Full Title: An open label, single arm trial evaluating the efficacy and safety of EVX-01 in combination with pembrolizumab in checkpoint inhibitor treatment naïve adults with unresectable or metastatic melanoma | ||
Medical condition: unresectable or metastatic melanoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Trial now transitioned) FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004850-31 | Sponsor Protocol Number: C4221016 | Start Date*: 2021-07-29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE METASTATIC OR UNRES... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Metastatic or unresectable locally advanced BRAF V600E/K mutation positive melanoma | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Trial now transitioned) HU (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) AT (Prematurely Ended) SK (Trial now transitioned) CZ (Trial now transitioned) NO (Prematurely Ended) PL (Trial now transitioned) GR (Trial now transitioned) FI (Trial now transitioned) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004314-34 | Sponsor Protocol Number: CaEP-R | Start Date*: 2019-12-05 | |||||||||||
Sponsor Name:Julie Gehl | |||||||||||||
Full Title: PHASE II INVESTIGATION OF CALCIUM ELECTROPORATION AS A TREATMENT FOR CUTANEOUS AND SUBCUTANEOUS MALIGNANT TUMOURS | |||||||||||||
Medical condition: Cutaneous or subcutaneous malignant tumours | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) DE (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023757-11 | Sponsor Protocol Number: myDC/pDCinstageIIImelanoma | Start Date*: 2014-11-06 |
Sponsor Name:Radboud University Nijmegen Medical Centre | ||
Full Title: Myeloid and plasmacytoid blood dendritic cells for immunotherapy of stage III melanoma patients scheduled for radical lymph node dissection | ||
Medical condition: melanoma patients with regional lymph node metastases (stage III) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-001399-13 | Sponsor Protocol Number: 69HCL19_0115 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Hospices Civils de Lyon | |||||||||||||
Full Title: MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable NRAS Melanoma: A Phase Ib/II Trial of Trametinib plus Hydroxychloroquine in Patients with NRAS Melanoma. CHLORO TRAM MEL | |||||||||||||
Medical condition: Patients with metastatic NRAS melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-005228-27 | Sponsor Protocol Number: INTERIM17 | Start Date*: 2017-10-05 |
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust | ||
Full Title: INTERIM: a randomised phase II feasibility study of INTERmittent versus continuous dosing of oral targeted combination therapy In patients with BRAFV600 mutant stage 3 unresectable or metastatic Me... | ||
Medical condition: BRAFV600 mutant stage 3 unresectable or metastatic melanoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2021-004594-32 | Sponsor Protocol Number: IO102-IO103-013/MK3475-D18 | Start Date*: 2022-02-16 | |||||||||||
Sponsor Name:IO Biotech ApS | |||||||||||||
Full Title: An open-label, randomized, Phase 3 clinical trial of IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic (adv... | |||||||||||||
Medical condition: Patients with previously untreated, unresectable or metastatic (advanced) melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) DK (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) IE (Prematurely Ended) BE (Trial now transitioned) HU (Trial now transitioned) PT (Completed) PL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
